Copyright Reports & Markets. All rights reserved.

Global Fibromyalgia Treatment Drug Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Fibromyalgia Treatment Drug Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Cymbalta (Duloxetine)
    • 1.2.3 Savella (Milnacipran)
    • 1.2.4 Lyrica (Pregabalin)
    • 1.2.5 Pancuronium
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Fibromyalgia Treatment Drug Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Household
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Fibromyalgia Treatment Drug Market Perspective (2015-2026)
  • 2.2 Global Fibromyalgia Treatment Drug Growth Trends by Regions
    • 2.2.1 Fibromyalgia Treatment Drug Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Fibromyalgia Treatment Drug Historic Market Share by Regions (2015-2020)
    • 2.2.3 Fibromyalgia Treatment Drug Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Fibromyalgia Treatment Drug Players by Market Size
    • 3.1.1 Global Top Fibromyalgia Treatment Drug Players by Revenue (2015-2020)
    • 3.1.2 Global Fibromyalgia Treatment Drug Revenue Market Share by Players (2015-2020)
  • 3.2 Global Fibromyalgia Treatment Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Fibromyalgia Treatment Drug Revenue
  • 3.4 Global Fibromyalgia Treatment Drug Market Concentration Ratio
    • 3.4.1 Global Fibromyalgia Treatment Drug Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Fibromyalgia Treatment Drug Revenue in 2019
  • 3.5 Key Players Fibromyalgia Treatment Drug Area Served
  • 3.6 Key Players Fibromyalgia Treatment Drug Product Solution and Service
  • 3.7 Date of Enter into Fibromyalgia Treatment Drug Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Fibromyalgia Treatment Drug Breakdown Data by Type (2015-2026)

  • 4.1 Global Fibromyalgia Treatment Drug Historic Market Size by Type (2015-2020)
  • 4.2 Global Fibromyalgia Treatment Drug Forecasted Market Size by Type (2021-2026)

5 Fibromyalgia Treatment Drug Breakdown Data by Application (2015-2026)

  • 5.1 Global Fibromyalgia Treatment Drug Historic Market Size by Application (2015-2020)
  • 5.2 Global Fibromyalgia Treatment Drug Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Fibromyalgia Treatment Drug Market Size (2015-2026)
  • 6.2 North America Fibromyalgia Treatment Drug Market Size by Type (2015-2020)
  • 6.3 North America Fibromyalgia Treatment Drug Market Size by Application (2015-2020)
  • 6.4 North America Fibromyalgia Treatment Drug Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Fibromyalgia Treatment Drug Market Size (2015-2026)
  • 7.2 Europe Fibromyalgia Treatment Drug Market Size by Type (2015-2020)
  • 7.3 Europe Fibromyalgia Treatment Drug Market Size by Application (2015-2020)
  • 7.4 Europe Fibromyalgia Treatment Drug Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Fibromyalgia Treatment Drug Market Size (2015-2026)
  • 8.2 China Fibromyalgia Treatment Drug Market Size by Type (2015-2020)
  • 8.3 China Fibromyalgia Treatment Drug Market Size by Application (2015-2020)
  • 8.4 China Fibromyalgia Treatment Drug Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Fibromyalgia Treatment Drug Market Size (2015-2026)
  • 9.2 Japan Fibromyalgia Treatment Drug Market Size by Type (2015-2020)
  • 9.3 Japan Fibromyalgia Treatment Drug Market Size by Application (2015-2020)
  • 9.4 Japan Fibromyalgia Treatment Drug Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Fibromyalgia Treatment Drug Market Size (2015-2026)
  • 10.2 Southeast Asia Fibromyalgia Treatment Drug Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Fibromyalgia Treatment Drug Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Fibromyalgia Treatment Drug Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Pfizer
    • 11.1.1 Pfizer Company Details
    • 11.1.2 Pfizer Business Overview
    • 11.1.3 Pfizer Fibromyalgia Treatment Drug Introduction
    • 11.1.4 Pfizer Revenue in Fibromyalgia Treatment Drug Business (2015-2020))
    • 11.1.5 Pfizer Recent Development
  • 11.2 Eli Lilly
    • 11.2.1 Eli Lilly Company Details
    • 11.2.2 Eli Lilly Business Overview
    • 11.2.3 Eli Lilly Fibromyalgia Treatment Drug Introduction
    • 11.2.4 Eli Lilly Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.2.5 Eli Lilly Recent Development
  • 11.3 Actavis Generics
    • 11.3.1 Actavis Generics Company Details
    • 11.3.2 Actavis Generics Business Overview
    • 11.3.3 Actavis Generics Fibromyalgia Treatment Drug Introduction
    • 11.3.4 Actavis Generics Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.3.5 Actavis Generics Recent Development
  • 11.4 Merck Sharp and Dohme
    • 11.4.1 Merck Sharp and Dohme Company Details
    • 11.4.2 Merck Sharp and Dohme Business Overview
    • 11.4.3 Merck Sharp and Dohme Fibromyalgia Treatment Drug Introduction
    • 11.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.4.5 Merck Sharp and Dohme Recent Development
  • 11.5 Daiichi Sankyo
    • 11.5.1 Daiichi Sankyo Company Details
    • 11.5.2 Daiichi Sankyo Business Overview
    • 11.5.3 Daiichi Sankyo Fibromyalgia Treatment Drug Introduction
    • 11.5.4 Daiichi Sankyo Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.5.5 Daiichi Sankyo Recent Development
  • 11.6 Innovative Med Concepts
    • 11.6.1 Innovative Med Concepts Company Details
    • 11.6.2 Innovative Med Concepts Business Overview
    • 11.6.3 Innovative Med Concepts Fibromyalgia Treatment Drug Introduction
    • 11.6.4 Innovative Med Concepts Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.6.5 Innovative Med Concepts Recent Development
  • 11.7 Meda
    • 11.7.1 Meda Company Details
    • 11.7.2 Meda Business Overview
    • 11.7.3 Meda Fibromyalgia Treatment Drug Introduction
    • 11.7.4 Meda Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.7.5 Meda Recent Development
  • 11.8 Meiji Seika
    • 11.8.1 Meiji Seika Company Details
    • 11.8.2 Meiji Seika Business Overview
    • 11.8.3 Meiji Seika Fibromyalgia Treatment Drug Introduction
    • 11.8.4 Meiji Seika Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.8.5 Meiji Seika Recent Development
  • 11.9 Switch Biotech
    • 11.9.1 Switch Biotech Company Details
    • 11.9.2 Switch Biotech Business Overview
    • 11.9.3 Switch Biotech Fibromyalgia Treatment Drug Introduction
    • 11.9.4 Switch Biotech Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.9.5 Switch Biotech Recent Development
  • 11.10 Theravance
    • 11.10.1 Theravance Company Details
    • 11.10.2 Theravance Business Overview
    • 11.10.3 Theravance Fibromyalgia Treatment Drug Introduction
    • 11.10.4 Theravance Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 11.10.5 Theravance Recent Development
  • 11.11 Zynerba Pharmaceuticals
    • 10.11.1 Zynerba Pharmaceuticals Company Details
    • 10.11.2 Zynerba Pharmaceuticals Business Overview
    • 10.11.3 Zynerba Pharmaceuticals Fibromyalgia Treatment Drug Introduction
    • 10.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.11.5 Zynerba Pharmaceuticals Recent Development
  • 11.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
    • 10.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
    • 10.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
    • 10.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Treatment Drug Introduction
    • 10.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
  • 11.13 Daiichi Sankyo
    • 10.13.1 Daiichi Sankyo Company Details
    • 10.13.2 Daiichi Sankyo Business Overview
    • 10.13.3 Daiichi Sankyo Fibromyalgia Treatment Drug Introduction
    • 10.13.4 Daiichi Sankyo Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.13.5 Daiichi Sankyo Recent Development
  • 11.14 Forest Pharmaceuticals, Inc.
    • 10.14.1 Forest Pharmaceuticals, Inc. Company Details
    • 10.14.2 Forest Pharmaceuticals, Inc. Business Overview
    • 10.14.3 Forest Pharmaceuticals, Inc. Fibromyalgia Treatment Drug Introduction
    • 10.14.4 Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.14.5 Forest Pharmaceuticals, Inc. Recent Development
  • 11.15 Boehringer Ingelheim GmbH
    • 10.15.1 Boehringer Ingelheim GmbH Company Details
    • 10.15.2 Boehringer Ingelheim GmbH Business Overview
    • 10.15.3 Boehringer Ingelheim GmbH Fibromyalgia Treatment Drug Introduction
    • 10.15.4 Boehringer Ingelheim GmbH Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.15.5 Boehringer Ingelheim GmbH Recent Development
  • 11.16 Pierre Fabre Medicament
    • 10.16.1 Pierre Fabre Medicament Company Details
    • 10.16.2 Pierre Fabre Medicament Business Overview
    • 10.16.3 Pierre Fabre Medicament Fibromyalgia Treatment Drug Introduction
    • 10.16.4 Pierre Fabre Medicament Revenue in Fibromyalgia Treatment Drug Business (2015-2020)
    • 10.16.5 Pierre Fabre Medicament Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Fibromyalgia Treatment Drug Scope and Market Size
    Fibromyalgia Treatment Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fibromyalgia Treatment Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Cymbalta (Duloxetine)
    Savella (Milnacipran)
    Lyrica (Pregabalin)
    Pancuronium
    Others

    Market segment by Application, split into
    Hospital
    Clinic
    Household
    Others

    Based on regional and country-level analysis, the Fibromyalgia Treatment Drug market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Fibromyalgia Treatment Drug market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Pfizer
    Eli Lilly
    Actavis Generics
    Merck Sharp and Dohme
    Daiichi Sankyo
    Innovative Med Concepts
    Meda
    Meiji Seika
    Switch Biotech
    Theravance
    Zynerba Pharmaceuticals
    Tonix Pharmaceuticals Holding Corp. (TNXP)
    Daiichi Sankyo
    Forest Pharmaceuticals, Inc.
    Boehringer Ingelheim GmbH
    Pierre Fabre Medicament

    Buy now